ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0521

Examination of Differential Response to Treatment with Mycophenolate Mofetil in Black and White Patients with Systemic Sclerosis
Abstract Number: 1123

Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
Abstract Number: PP11

Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Abstract Number: 0846

Exercise Identity at the Start of Outpatient Physical Therapy Prospectively Predicts Physical Activity at 12-weeks After Total Knee Replacement
Abstract Number: 0337

Expanded Autoantibody Profiling in Incomplete Lupus Erythematosus
Abstract Number: 1164

Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience
Abstract Number: 0599

Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
Abstract Number: 0776

Expert Clinical Management of Immune-related Inflammatory Arthritis: Results from a Multicenter International Expert Survey
Abstract Number: 0275

Exploratory Analysis of Filgotinib Safety Data in Patients with Moderately to Severely Active RA and an Increased Risk of Cardiovascular Events: Data from Phase 2 and 3 Clinical Trials
Abstract Number: 1542

Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Abstract Number: 0933

Exploratory Study of the Usefulness of TNFAIP3 Genetic Variants in Predicting Response to Methotrexate in Early Arthritis Patients
Abstract Number: 1334

Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)
Abstract Number: 1783

Exploring How and Why Organizations Identify, Adopt, Disseminate, and Sustain Evidence-based Programs for Latinos with Arthritis
Abstract Number: 0184

Exploring Patient Journeys and Education Needs of Hispanic Individuals with Rheumatoid Arthritis
Abstract Number: 0963

Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].